Janus Kinase 1 in Vitiligo & Psoriasis

Cairo University (CU)

Status: Completed

Conditions: Vitiligo

Treatments: Other: skin biopsy

Study type: Interventional

Funder types: Other

Identifiers

NCT03762551

Dermatology 11

Details and patient eligibility

About

Assessment of the level of JAK1 in both vitiligo and psoriasis patients before and after treatment with NB-UVB which is considered a gold standard therapy for both diseases.

Enrollment: 30 patients

Sex: All

Ages: 12+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• age above 12 years of age.
• psoriasis vulgaris or non-segmental vitiligo
• patients who received no systemic or topical treatment at least 6 weeks prior to enrollment into the study.

Exclusion criteria

• psoriasis patients with erythrodermic psoriasis, pustular psoriasis or associated psoriatic arthritis
• vitiligo patients with segmental or universal vitiligo were excluded from the study.
• any patient with a photosensitive disorder or any contraindication to phototherapy exposure, e.g., history or presence of malignant or premalignant skin lesions.

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

30 participants in 3 patient groups

vitiligo

Experimental group

Description:

assess the level of JAK1 in vitiligo patients before and after treatment with NB-UVB

Treatment:

Other: skin biopsy

psoriasis

Active Comparator group

Description:

assess the level of JAK1 in psoriasis patients before and after treatment with NB-UVB

Treatment:

Other: skin biopsy

controls

Other group

Description:

assess the level of JAK1 in controls

Treatment:

Other: skin biopsy